The meeting of the Board of Directors of the Company was held on May 27, 2026 which approved and took on record the Audited Standalone and Consolidated Financial Results of the Company ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 0.6 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
GKB Ophthalmics' Board approved audited FY2025-26 results. Standalone revenue fell 21.7% to ₹2,564.41 Lakhs (from ₹3,274.94 Lakhs), with a net loss of ₹356.79 Lakhs (prior year loss ₹610.79 Lakhs). Consolidated revenue rose 36.8% to ₹14,906.35 Lakhs (from ₹10,898.76 Lakhs), though net loss stood at ₹1,014.70 Lakhs. The Board skipped dividend for FY2025-26. Exceptional items of ₹178.99 Lakhs were recorded due to incremental gratuity/leave liabilities under new Indian labour codes. GSV Ophthalmics Private Limited, a former subsidiary, was voluntarily wound up and its ₹11.70 Crore investment fully realised. K.G. Gupta (Chairman & MD) and Cedric Lobo (Whole Time Director) were reappointed subject to shareholder approval. Auditors issued an unmodified opinion.
The company remains loss-making on both standalone and consolidated bases, though losses have narrowed. Revenue decline on standalone operations and the dividend skip signal continued financial stress. The disposal of GSV and strong consolidated revenue growth (including overseas subsidiaries) are bright spots but insufficient to restore profitability.